XLO vs. ELDN, CCCC, THTX, PEPG, MOLN, NKTX, ANRO, NVCT, CRDF, and ACOG
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Eledon Pharmaceuticals (ELDN), C4 Therapeutics (CCCC), Theratechnologies (THTX), PepGen (PEPG), Molecular Partners (MOLN), Nkarta (NKTX), Alto Neuroscience (ANRO), Nuvectis Pharma (NVCT), Cardiff Oncology (CRDF), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs. Its Competitors
Eledon Pharmaceuticals (NASDAQ:ELDN) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Eledon Pharmaceuticals has higher earnings, but lower revenue than Xilio Therapeutics. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.27 indicating that Xilio Therapeutics is being referred to more favorably in the news media.
Eledon Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Eledon Pharmaceuticals' return on equity of -92.51% beat Xilio Therapeutics' return on equity.
56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Eledon Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 186.53%. Xilio Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 297.14%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Eledon Pharmaceuticals.
Summary
Eledon Pharmaceuticals beats Xilio Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 10/21/2025 by MarketBeat.com Staff
Free XLO Stock Alerts